AUSTIN, Texas / Aug 06, 2024 / Business Wire / agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced results for the second quarter ended June 30, 2024.
"Our second quarter results were in-line with our guidance, and we are maintaining medical margin and Adjusted EBITDA guidance for the full year," said Steve Sell, chief executive officer. "We continue to make progress implementing our performance action plan which should contribute to accelerating our profitability over time and strengthening our value proposition to physicians and payers."
Second Quarter 2024 Results:
Key Financial and Operating Metrics ($M): (Second Quarter 2024 vs. 2023) | |||||
| Three Months Ended June 30, |
|
Change | ||
| 2024 |
| 2023 |
| % YoY |
Medicare Advantage Members1 | 512,800 |
| 372,800 |
| 38% |
ACO Model Members1, 2 | 131,700 |
| 87,000 |
| 51% |
Total Members Live on Platform1, 2 | 644,600 |
| 459,800 |
| 40% |
Avg. Medicare Advantage Members | 507,000 |
| 373,500 |
| 36% |
Total revenues | $1,483 |
| $1,069 |
| 39% |
Gross Profit | $32 |
| $55 |
| (41%) |
Medical Margin | $106 |
| $134 |
| (21%) |
Net (Loss) Income | ($31) |
| ($17) |
| (83%) |
Adjusted EBITDA3 | ($3) |
| $12 |
| NM |
Geography Entry Costs | $5 |
| $19 |
| (74%) |
| |||||
Continued Progress on Performance Action Plan
agilon health is making tangible progress against its targeted action plan to improve performance. This plan includes refining payor relationships, increasing engagement among PCPs to reduce variability, improving data visibility and analytics, and accelerating operating efficiency.
agilon health continues to make progress on obtaining favorable health plan agreements across markets and payer types. The company continues to deploy structured training and local medical director engagement with PCPs. In the second quarter, this activity covered 20 markets and ~75% of PCPs in the model. agilon achieved its target of onboarding ~75% of member data into the company's financial data pipeline and expects to onboard the remaining balance through the second half of 2024. The company continues to focus on improving operating expense efficiency; platform support costs accounted for 2.8% of revenue in the second quarter, compared to the company's 3% target for 2024.
Capital Position and Balance Sheet:
agilon health’s balance sheet as of June 30, 2024 included cash, cash equivalents and marketable securities of $408 million and total debt of $36 million. At the end of the quarter agilon health had $104 million of cash associated with the company’s unconsolidated ACO model entities.
Outlook for Fiscal Year 2024 ($M): | |||||||
Year Ended December 31, 2024 | |||||||
Updated Guidance | Previous Guidance | ||||||
Low | High | Low | High | ||||
Medicare Advantage Members1 | 518,000 |
| 520,000 |
| 510,000 |
| 515,000 |
ACO Model Members1,2 | 123,000 |
| 128,000 |
| 120,000 |
| 125,000 |
Total Members Live on Platform1 | 641,000 |
| 648,000 |
| 630,000 |
| 640,000 |
Avg. Medicare Advantage Members | 513,000 |
| 514,000 |
| 510,000 |
| 514,000 |
Total Revenues | $6,010 |
| $6,040 |
| $6,125 |
| $6,175 |
Medical Margin | $400 |
| $450 |
| $400 |
| $450 |
Adjusted EBITDA3 | ($60) |
| ($15) |
| ($60) |
| ($15) |
Geography Entry Costs4 | $55 |
| $45 |
| $65 |
| $55 |
| |||||||
Outlook for Third Quarter 2024 ($M): | |||
|
| ||
Quarter Ended September 30, 2024 | |||
Low | High | ||
Medicare Advantage Members1 | 514,000 |
| 516,000 |
ACO Model Members1,2 | 125,000 |
| 130,000 |
Total Members Live on Platform1 | 639,000 |
| 646,000 |
Avg. Medicare Advantage Members | 511,000 |
| 513,000 |
Total Revenues | $1,465 |
| $1,475 |
Medical Margin | $90 |
| $110 |
Adjusted EBITDA3 | ($30) |
| ($10) |
Geography Entry Costs4 | $19 |
| $14 |
| |||
The company has not reconciled guidance for medical margin to gross profit or adjusted EBITDA to net income (loss), the most comparable GAAP measures, and has not provided forward-looking guidance for net income (loss) in each case because of the uncertainty around certain items that may impact gross profit or net income (loss), including non-cash stock-based compensation.
Webcast and Conference Call
agilon health will host a conference call to discuss second quarter 2024 results on Tuesday, August 6, 2024 at 4:30 PM Eastern Time. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 689044. A simultaneous webcast can be accessed by visiting the “Events & Presentations” section of agilon’s Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.
About agilon health
agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 3,000+ PCPs that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in 30+ diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information visit www.agilonhealth.com and connect with us on Instagram, LinkedIn and YouTube.
Forward-Looking Statements
Statements in this release that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “seeks,” “aims,” “projects,” “is optimistic,” “intends,” “plans,” “estimates,” “anticipates” or the negative versions of these words or other comparable terms. Examples of forward-looking statements include, among other things: statements regarding our expectations related to operating and financial results, the value of our full-risk model for primary care physicians, the acceleration of profitability over time, the strengthening of our value proposition to physicians and payers, and our long-term opportunities and strategic growth plans, expected revenue, medical costs, net income and gross profit, total and average membership, Adjusted EBITDA, Medical Margin, geography entry costs and other financial projections and assumptions, including our fiscal year and third quarter 2024 guidance. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. These risks and uncertainties that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, but are not limited to: our history of net losses and the expectation that our expenses will increase in the future; failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives; success in executing our operating strategies or achieving results consistent with our historical performance; medical expenses incurred on behalf of our members may exceed revenues we receive; our ability to secure contracts with Medicare Advantage payors; our ability to grow new physician partner relationships sufficient to recover startup costs; availability of additional capital, on acceptable terms or at all, to support our business in the future; significant reduction in our membership; transition to a Total Care Model may be challenging for physician partners; public health crises, such as COVID-19, could adversely affect us; inaccuracy in estimates of our members’ risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts; the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners; our ability to hire and retain qualified personnel; our ability to realize the full value of our intangible assets; security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems; our ability to protect the confidentiality of our know-how and other proprietary and internally developed information; reliance on our subsidiaries; Environmental, Social, and Governance issues; reliance on a limited number of key payors; the limited terms of contracts with our payors and our ability to renew them upon expiration; reliance on our payors, physician partners and other providers to operate our business; our ability to obtain accurate and complete diagnosis data; reliance on third-party software, data, infrastructure and bandwidth; consolidation and competition in the healthcare industry; the impact of changes to, and dependence on, federal government healthcare programs; uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures; regulation of the healthcare industry and our and our physician partners’ ability to comply with such laws and regulations; federal and state investigations, audits and enforcement actions; repayment obligations arising out of payor audits; negative publicity regarding the managed healthcare industry generally; our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data; failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization; lawsuits not covered by insurance; changes in tax laws and regulations, or changes in related judgments or assumptions; our indebtedness and our potential to incur more debt; dependence on our subsidiaries for cash to fund all of our operations and expenses; provisions in our governing documents; ability to achieve a return on your investment depends on appreciation in the price of our common stock; the material weakness in our internal control over financial reporting and our ability to remediate such material weakness; and risks related to other factors discussed in our filings with the Securities and Exchange Commission (the “SEC”), including the factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which can be found at the SEC’s website at www.sec.gov. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
agilon health, inc. Condensed Consolidated Balance Sheets In thousands, except per share data | |||||||
| June 30, 2024 |
| December 31, 2023 | ||||
| (unaudited) |
|
| ||||
ASSETS |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 109,490 |
|
| $ | 107,570 |
|
Restricted cash and equivalents |
| 6,846 |
|
|
| 6,759 |
|
Marketable securities |
| 291,622 |
|
|
| 380,773 |
|
Receivables, net |
| 1,437,040 |
|
|
| 942,461 |
|
Prepaid expenses and other current assets, net |
| 39,012 |
|
|
| 42,513 |
|
Total current assets |
| 1,884,010 |
|
|
| 1,480,076 |
|
Property and equipment, net |
| 27,821 |
|
|
| 27,576 |
|
Intangible assets, net |
| 74,821 |
|
|
| 63,769 |
|
Goodwill |
| 24,133 |
|
|
| 24,133 |
|
Other assets |
| 152,530 |
|
|
| 145,312 |
|
Total assets | $ | 2,163,315 |
|
| $ | 1,740,866 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Medical claims and related payables | $ | 1,097,664 |
|
| $ | 737,724 |
|
Accounts payable and accrued expenses |
| 280,899 |
|
|
| 233,182 |
|
Current portion of long-term debt |
| 8,750 |
|
|
| 6,250 |
|
Total current liabilities |
| 1,387,313 |
|
|
| 977,156 |
|
Long-term debt, net of current portion |
| 27,360 |
|
|
| 32,308 |
|
Other liabilities |
| 72,775 |
|
|
| 70,381 |
|
Total liabilities |
| 1,487,448 |
|
|
| 1,079,845 |
|
|
|
|
| ||||
Commitments and contingencies |
|
|
| ||||
|
|
|
| ||||
Stockholders' equity (deficit): |
|
|
| ||||
Common stock, $0.01 par value: 2,000,000 shares authorized; 411,447 and 406,387 shares issued and outstanding, respectively |
| 4,114 |
|
|
| 4,064 |
|
Additional paid-in capital |
| 2,038,540 |
|
|
| 1,986,899 |
|
Accumulated deficit |
| (1,363,572 | ) |
|
| (1,326,826 | ) |
Accumulated other comprehensive income (loss) |
| (2,447 | ) |
|
| (2,298 | ) |
Total agilon health, inc. stockholders' equity (deficit) |
| 676,635 |
|
|
| 661,839 |
|
Noncontrolling interests |
| (768 | ) |
|
| (818 | ) |
Total stockholders’ equity (deficit) |
| 675,867 |
|
|
| 661,021 |
|
Total liabilities and stockholders’ equity (deficit) | $ | 2,163,315 |
|
| $ | 1,740,866 |
|
agilon health, inc. Condensed Consolidated Statements of Operations In thousands, except per share data (unaudited) | |||||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
|
|
|
|
|
|
|
| ||||||||
Revenues: |
|
|
|
|
|
|
| ||||||||
Medical services revenue | $ | 1,479,579 |
|
| $ | 1,067,234 |
|
| $ | 3,080,774 |
|
| $ | 2,120,353 |
|
Other operating revenue |
| 3,179 |
|
|
| 1,881 |
|
|
| 6,338 |
|
|
| 3,074 |
|
Total revenues |
| 1,482,758 |
|
|
| 1,069,115 |
|
|
| 3,087,112 |
|
|
| 2,123,427 |
|
Expenses: |
|
|
|
|
|
|
| ||||||||
Medical services expense |
| 1,374,060 |
|
|
| 932,823 |
|
|
| 2,817,902 |
|
|
| 1,830,395 |
|
Other medical expenses |
| 76,523 |
|
|
| 81,716 |
|
|
| 161,947 |
|
|
| 165,333 |
|
General and administrative (including noncash stock-based compensation expense of $18,207, $19,446, $35,116, and $33,031, respectively) |
| 69,612 |
|
|
| 79,254 |
|
|
| 146,034 |
|
|
| 149,006 |
|
Depreciation and amortization |
| 5,907 |
|
|
| 4,279 |
|
|
| 11,751 |
|
|
| 7,233 |
|
Total expenses |
| 1,526,102 |
|
|
| 1,098,072 |
|
|
| 3,137,634 |
|
|
| 2,151,967 |
|
Income (loss) from operations |
| (43,344 | ) |
|
| (28,957 | ) |
|
| (50,522 | ) |
|
| (28,540 | ) |
Other income (expense): |
|
|
|
|
|
|
| ||||||||
Income (loss) from equity method investments |
| 9,955 |
|
|
| 8,472 |
|
|
| 15,639 |
|
|
| 9,848 |
|
Other income (expense), net |
| 4,841 |
|
|
| 7,087 |
|
|
| 10,733 |
|
|
| 14,979 |
|
Interest expense |
| (1,697 | ) |
|
| (1,555 | ) |
|
| (2,981 | ) |
|
| (3,048 | ) |
Income (loss) before income taxes |
| (30,245 | ) |
|
| (14,953 | ) |
|
| (27,131 | ) |
|
| (6,761 | ) |
Income tax benefit (expense) |
| (417 | ) |
|
| (1,073 | ) |
|
| (284 | ) |
|
| 686 |
|
Income (loss) from continuing operations |
| (30,662 | ) |
|
| (16,026 | ) |
|
| (27,415 | ) |
|
| (6,075 | ) |
Discontinued operations: |
|
|
|
|
|
|
| ||||||||
Income (loss) before gain (loss) on sales |
| — |
|
|
| (769 | ) |
|
| (518 | ) |
|
| 5,239 |
|
Gain (loss) on sales of assets, net |
| — |
|
|
| — |
|
|
| (8,763 | ) |
|
| — |
|
Total discontinued operations |
| — |
|
|
| (769 | ) |
|
| (9,281 | ) |
|
| 5,239 |
|
Net income (loss) |
| (30,662 | ) |
|
| (16,795 | ) |
|
| (36,696 | ) |
|
| (836 | ) |
Noncontrolling interests’ share in (earnings) loss |
| (20 | ) |
|
| 46 |
|
|
| (50 | ) |
|
| 109 |
|
Net income (loss) attributable to common shares | $ | (30,682 | ) |
| $ | (16,749 | ) |
| $ | (36,746 | ) |
| $ | (727 | ) |
|
|
|
|
|
|
|
| ||||||||
Net income (loss) per common share, basic and diluted |
|
|
|
|
|
|
| ||||||||
Continuing operations | $ | (0.07 | ) |
| $ | (0.04 | ) |
| $ | (0.07 | ) |
| $ | (0.01 | ) |
Discontinued operations | $ | — |
|
| $ | — |
|
| $ | (0.02 | ) |
| $ | 0.01 |
|
Weighted average shares outstanding |
|
|
|
|
|
|
| ||||||||
Basic |
| 411,271 |
|
|
| 410,338 |
|
|
| 409,152 |
|
|
| 411,748 |
|
Diluted |
| 411,271 |
|
|
| 410,338 |
|
|
| 409,152 |
|
|
| 411,748 |
|
agilon health, inc. Condensed Consolidated Statements of Cash Flows In thousands (unaudited) | |||||||
| Six Months Ended June 30, | ||||||
| 2024 |
| 2023 | ||||
Cash flows from operating activities: |
|
|
| ||||
Net income (loss) | $ | (36,696 | ) |
| $ | (836 | ) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
| ||||
Depreciation and amortization |
| 11,751 |
|
|
| 9,704 |
|
Stock-based compensation expense |
| 35,116 |
|
|
| 33,244 |
|
Loss (income) from equity method investments |
| (15,639 | ) |
|
| (9,848 | ) |
Distributions of earnings from equity method investments |
| 3,340 |
|
|
| — |
|
(Gain) loss on sale of assets, net and impairments |
| 3,784 |
|
|
| — |
|
Other noncash items |
| (837 | ) |
|
| (2,322 | ) |
Changes in operating assets and liabilities: |
| (67,312 | ) |
|
| (111,957 | ) |
Net cash provided by (used in) operating activities |
| (66,493 | ) |
|
| (82,015 | ) |
Cash flows from investing activities: |
|
|
| ||||
Purchase of property and equipment |
| (6,451 | ) |
|
| (7,811 | ) |
Purchase of intangible assets |
| (17,893 | ) |
|
| (1,837 | ) |
Investment in loans receivable and other |
| (9,742 | ) |
|
| (8,468 | ) |
Investments in marketable securities |
| (12,006 | ) |
|
| (65,568 | ) |
Proceeds from maturities of marketable securities and other |
| 115,747 |
|
|
| 97,269 |
|
Net cash paid in business combination |
| — |
|
|
| (44,367 | ) |
Net cash provided by (used in) investing activities |
| 69,655 |
|
|
| (30,782 | ) |
Cash flows from financing activities: |
|
|
| ||||
Proceeds from equity issuances, net |
| 1,345 |
|
|
| 8,802 |
|
Common stock repurchase |
| — |
|
|
| (200,000 | ) |
Repayments of long-term debt |
| (2,500 | ) |
|
| (2,500 | ) |
Net cash provided by (used in) financing activities |
| (1,155 | ) |
|
| (193,698 | ) |
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents |
| 2,007 |
|
|
| (306,495 | ) |
Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period |
| 114,329 |
|
|
| 475,912 |
|
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period |
| — |
|
|
| 31,768 |
|
Cash, cash equivalents and restricted cash and equivalents, beginning of period |
| 114,329 |
|
|
| 507,680 |
|
Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period |
| 116,336 |
|
|
| 184,550 |
|
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period |
| — |
|
|
| 16,635 |
|
Cash, cash equivalents and restricted cash and equivalents, end of period | $ | 116,336 |
|
| $ | 201,185 | |
agilon health, inc. Key Operating Metrics In thousands (unaudited) | |||||||||||||||
GROSS PROFIT | |||||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
Total revenues | $ | 1,482,758 |
|
| $ | 1,069,115 |
|
| $ | 3,087,112 |
|
| $ | 2,123,427 |
|
Medical services expense |
| (1,374,060 | ) |
|
| (932,823 | ) |
|
| (2,817,902 | ) |
|
| (1,830,395 | ) |
Other medical expenses(1) |
| (76,523 | ) |
|
| (81,716 | ) |
|
| (161,947 | ) |
|
| (165,333 | ) |
Gross profit | $ | 32,175 |
|
| $ | 54,576 |
|
| $ | 107,263 |
|
| $ | 127,699 |
|
______________________________________________________________ | ||
(1) | Represents physician compensation expense related to surplus sharing and other care management expenses that help to create medical cost efficiency. Includes costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2024 and 2023, costs incurred in implementing geographies were $18,000 and $7.7 million, respectively. For the six months ended June 30, 2024 and 2023, costs incurred in implementing geographies were $0.6 million and $10.0 million, respectively. | |
GENERAL AND ADMINISTRATIVE COSTS, INCLUDING PLATFORM SUPPORT COSTS | |||||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
Platform support costs | $ | 41,687 |
| $ | 42,041 |
| $ | 87,399 |
| $ | 85,333 | ||||
Geography entry costs(1) |
| 4,866 |
|
|
| 11,306 |
|
|
| 15,325 |
|
|
| 20,556 |
|
Severance and related costs |
| 868 |
|
|
| — |
|
|
| 3,283 |
|
|
| 188 |
|
Stock-based compensation expense |
| 18,207 |
|
|
| 19,446 |
|
|
| 35,116 |
|
|
| 33,031 |
|
Other(2) |
| 3,984 |
|
|
| 6,461 |
|
|
| 4,911 |
|
|
| 9,898 |
|
General and administrative | $ | 69,612 |
|
| $ | 79,254 |
|
| $ | 146,034 |
|
| $ | 149,006 |
|
______________________________________________________________ | ||
(1) | Represents direct geography entry costs, including investments to develop and expand our platform and costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. | |
(2) | Includes transaction-related costs. | |
Our platform support costs, which include regionally-based support personnel and other operating costs to support our geographies, are expected to decrease over time as a percentage of revenue as our physician partners add members and our revenue grows. Our operating expenses at the enterprise level include resources and technology to support payor contracting, clinical program development, quality, data management, finance, and legal and compliance functions. | ||
agilon health, inc. Non-GAAP Financial Measures In thousands (unaudited) | |||||||||||||||
MEDICAL MARGIN | |||||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
Gross profit(1) | $ | 32,175 |
|
| $ | 54,576 |
|
| $ | 107,263 |
|
| $ | 127,699 |
|
Other operating revenue |
| (3,179 | ) |
|
| (1,881 | ) |
|
| (6,338 | ) |
|
| (3,074 | ) |
Other medical expenses |
| 76,523 |
|
|
| 81,716 |
|
|
| 161,947 |
|
|
| 165,333 |
|
Medical margin | $ | 105,519 |
|
| $ | 134,411 |
|
| $ | 262,872 |
|
| $ | 289,958 |
|
______________________________________________________________ | ||
(1) | Gross profit is defined as total revenues less medical services expense and other medical expenses. | |
ADJUSTED EBITDA | |||||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
Net income (loss)(1) | $ | (30,662 | ) |
| $ | (16,795 | ) |
| $ | (36,696 | ) |
| $ | (836 | ) |
(Income) loss from discontinued operations, net of income taxes |
| — |
|
|
| 769 |
|
|
| 9,281 |
|
|
| (5,239 | ) |
Interest expense |
| 1,697 |
|
|
| 1,555 |
|
|
| 2,981 |
|
|
| 3,048 |
|
Income tax expense (benefit) |
| 417 |
|
|
| 1,073 |
|
|
| 284 |
|
|
| (686 | ) |
Depreciation and amortization |
| 5,907 |
|
|
| 4,279 |
|
|
| 11,751 |
|
|
| 7,233 |
|
Severance and related costs |
| 868 |
|
|
| — |
|
|
| 3,283 |
|
|
| 188 |
|
Stock-based compensation expense |
| 18,207 |
|
|
| 19,446 |
|
|
| 35,116 |
|
|
| 33,031 |
|
EBITDA adjustments related to equity method investments |
| 1,404 |
|
|
| 2,757 |
|
|
| 5,306 |
|
|
| 4,724 |
|
Other(2) |
| (668 | ) |
|
| (615 | ) |
|
| (5,082 | ) |
|
| (4,956 | ) |
Adjusted EBITDA | $ | (2,830 | ) |
| $ | 12,469 |
|
| $ | 26,224 |
|
| $ | 36,507 |
|
______________________________________________________________ | ||
(1) | Includes direct geography entry costs, including investments to develop and expand our platform and costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2024 and 2023, (i) $18,000 and $7.7 million, respectively, are included in other medical expenses and (ii) $4.8 million and $11.3 million, respectively, are included in general and administrative expenses. For the six months ended June 30, 2024 and 2023, (i) $0.6 million and $10.0 million, respectively, are included in other medical expenses and (ii) $15.3 million and $20.6 million, respectively, are included in general and administrative expenses. | |
(2) | Includes interest income and transaction-related costs. | |
agilon health, inc. Supplemental Financial Information In thousands (unaudited) | |||||||||||||||
| Three Months Ended June 30, 2024 |
| Six Months Ended June 30, 2024 | ||||||||||||
| Medicare Advantage (Consolidated) |
| CMS ACO Models (Unconsolidated) |
| Medicare Advantage (Consolidated) |
| CMS ACO Models (Unconsolidated) | ||||||||
Medical services revenue | $ | 1,479,579 |
|
| $ | 446,914 |
|
| $ | 3,080,774 |
|
| $ | 887,074 |
|
Other operating revenue |
| 3,179 |
|
|
| — |
|
|
| 6,338 |
|
|
| — |
|
Total revenues |
| 1,482,758 |
|
|
| 446,914 |
|
|
| 3,087,112 |
|
|
| 887,074 |
|
Medical services expense |
| (1,374,060 | ) |
|
| (406,921 | ) |
|
| (2,817,902 | ) |
|
| (805,713 | ) |
Other medical expenses |
| (76,523 | ) |
|
| (22,268 | ) |
|
| (161,947 | ) |
|
| (47,673 | ) |
Gross profit |
| 32,175 |
|
|
| 17,725 |
|
|
| 107,263 |
|
|
| 33,688 |
|
Other operating revenue |
| (3,179 | ) |
|
| — |
|
|
| (6,338 | ) |
|
| — |
|
Other medical expenses |
| 76,523 |
|
|
| 22,268 |
|
|
| 161,947 |
|
|
| 47,673 |
|
Medical margin | $ | 105,519 |
|
| $ | 39,993 |
|
| $ | 262,872 |
|
| $ | 81,361 |
|
Certain of our operations are not consolidated for the period presented because we do not have the ability to control certain activities due to another party’s control of the entities’ board of directors. Although revenues of the unconsolidated operations are not recorded as revenues by us, income (loss) from equity method investments is nonetheless a significant portion of our overall earnings. See Note 14 to the Condensed Consolidated Financial Statements in the Quarterly Report on Form 10-Q for the period ending June 30, 2024 for additional discussion on our equity method investments. | |||||||||||||||
In addition to providing results that are determined in accordance with GAAP, we present Medical Margin and Adjusted EBITDA, which are non-GAAP financial measures. | |||||||||||||||
We define Medical Margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect Medical Margin to increase in absolute dollars. However, Medical Margin per member per month (PMPM) may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to Medical Margin PMPM. We believe this metric provides insight into the economics of our capitation arrangements as it includes all medical services expense directly associated with our members’ care. | |||||||||||||||
We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis. | |||||||||||||||
Gross profit is the most directly comparable GAAP measure to Medical Margin. Net income (loss) is the most directly comparable GAAP measure to Adjusted EBITDA. | |||||||||||||||
We believe Medical Margin and Adjusted EBITDA help identify underlying trends in our business and facilitate evaluation of period-to-period operating performance of our operations by eliminating items that are variable in nature and not considered by us in the evaluation of ongoing operating performance, allowing comparison of our recurring core business operating results over multiple periods. We also believe Medical Margin and Adjusted EBITDA provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to key metrics we use for financial and operational decision-making. We believe Medical Margin and Adjusted EBITDA or similarly titled non-GAAP measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance. Other companies may calculate Medical Margin and Adjusted EBITDA or similarly titled non-GAAP measures differently from the way we calculate these metrics. As a result, our presentation of Medical Margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, limiting their usefulness as comparative measures. | |||||||||||||||
| Last Trade: | US$1.89 |
| Daily Change: | 0.11 6.18 |
| Daily Volume: | 2,773,283 |
| Market Cap: | US$778.720M |
November 07, 2024 May 07, 2024 February 27, 2024 February 08, 2024 November 02, 2023 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
